drugset / Trial / NCT01186029

Comparison of Adding EMEND to PONV/PDNV Treatment Regimen

NCT01186029

RandomizedParallel-groupDouble-blindPrevention

Summary

This study is looking at whether the addition of Aprepitant (Emend), an antiemetic, will provide added efficacy if added to 2 drugs that are already used as a standard of care for post-operative nausea and vomiting and post-discharge nausea and vomiting.

Timeline

Start
2011-09-01
Primary completion
2011-09-01
Completion
2011-09-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aprepitant Other / unclassified 40 mg Oral

Indications

No indication recorded.